Aaron’s group is modality agnostic and exploits the “best” approach including bioactive peptides, degraders, small molecules, antibodies, covalent technologies and systems yet to be described.
Prior to joining Calico, Aaron completed a postdoc in Early Discovery Biochemistry at Genentech. There he developed and designed peptides through directed evolution, structural and in silico approaches that modulate Wnt-signaling. He also provided structural insights into how cell-surface FZD receptors recognize cis-unsaturated fatty acyl groups on Wnt ligands.
During his Ph.D. Aaron developed antagonistic small molecules that specifically disrupt PI4P signaling pathways in eukaryotic cells, superior to those directed against phosphatidylinositol hydroxyl kinases.